Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Decreases By 21.7%

enGene Holdings Inc. (NASDAQ:ENGNW) saw a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 7,709 shares, a decrease of 21.7% from the February 12th total of 9,849 shares. Based on an average daily volume of 3,318 shares, the short-interest ratio is currently 2.3 days. Based on an average daily volume of 3,318 shares, the short-interest ratio is currently 2.3 days.

enGene Stock Performance

ENGNW traded down $0.09 on Monday, reaching $2.46. 700 shares of the company traded hands, compared to its average volume of 20,448. The stock’s 50 day moving average price is $3.10 and its 200-day moving average price is $2.30. enGene has a 52-week low of $0.51 and a 52-week high of $4.20.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.